Validose solves patient non-adherence by enabling real-time action from precise insights to drive patient behavior, streamline decision-making, and enhance health outcomes.
Total raised: $2M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.02.2025 | Pre-Seed | $2M | - |
Mentions in press and media 4
| Date | Title | Description |
| 27.02.2025 | Validose: $2 Million (Pre-Seed) Raised For Clinical Trial Medication Adherence Platform | Validose, a 10XBeta Venture Studio portfolio company pioneering precision medication delivery, announced recently the closing of a $2 million pre-seed funding round. The funding round was led by Peter Bauer’s Family Office as part of its Te... |
| 21.02.2025 | Validose: A New Dawn in Medication Adherence and Clinical Trials | In the bustling heart of New York City, a quiet revolution is brewing in the realm of healthcare technology. Validose, a precision medication delivery company, has recently secured $2 million in pre-seed funding. This funding, led by Peter ... |
| 20.02.2025 | Validose Raises $2M in Pre-Seed Funding | Validose, a NYC-based precision medication delivery company, raised $2M in Pre-Seed funding. The round was led by Peter Bauer’s Family Office as part of its Technology for Humanity strategy, 10XBeta, and Interstate Fusion Ventures. Angel in... |
| 18.02.2025 | Validose Raises $2M to Combat Clinical Trial Non-Adherence with AI-Powered Medication Delivery | What You Should Know: – Validose, a 10XBeta Venture Studio portfolio company pioneering precision medication delivery, announced today the successful close of a $2 million pre-seed funding round. – The round was led by Peter Bauer’s Family ... |